Publications by authors named "Yutaka Fujiwara"

Claim this Profile
S
Salvage Surgery Following Systemic Therapy in Initially Unresectable Non-Small Cell Lung Cancer.
Katsutoshi Seto, Yoshitsugu Horio, Katsuhiro Masago, Eiichi Sasaki, Hiroaki Kuroda, Yutaka Fujiwara

Thorac Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC.
Timothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Dae Ho Lee, Takafumi Koyama, Yutaka Fujiwara

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of full-time equivalent allocation on the effectiveness of antimicrobial stewardship activities: A multicenter study in Okayama, Japan.
Shiho Kajita, Hideharu Hagiya, Atsushi Okita, Yuto Haruki, Haruto Yamada, Yutaka Fujiwara

J Infect Chemother· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Shintaro Kanda, Seiji Niho, Takayasu Kurata, Shogo Nomura, Yosuke Kawashima, Yutaka Fujiwara

Clin Cancer Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smoking behavior-related genetic variants and lung cancer risk in Japanese: an assessment by mediation analysis.
Sayaka Yamamoto, Yuriko N Koyanagi, Yuji Iwashita, Tomohiro Shinozaki, Yutaka Fujiwara

Carcinogenesis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis.
Kazuhiro Shimomura, Takatsugu Ogata, Akimitsu Maeda, Yukiya Narita, Hiroya Taniguchi, Yutaka Fujiwara

Invest New Drugs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Yoshimasa Shiraishi, Shogo Nomura, Shunichi Sugawara, Hidehito Horinouchi, Yasuto Yoneshima, Yutaka Fujiwara

Lancet Respir Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors.
Ryo Kimura, Yuta Adachi, Kentaro Hirade, Satoru Kisoda, Shogo Yanase, Yutaka Fujiwara

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report.
Yutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, Teppei Yamaguchi, Naohiro Watanabe

Case Rep Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Magnesium Supplementation in Cancer Patients Developing Hypomagnesemia Due to Anti-EGFR Antibody: A Systematic Review.
Taigo Kato, Takahisa Kawaguchi, Taro Funakoshi, Yutaka Fujiwara, Yoshinari Yasuda

Cancer Diagn Progn· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis.
Teppei Yamaguchi, Junichi Shimizu, Reiko Matsuzawa, Naohiro Watanabe, Yoshitsugu Horio, Yutaka Fujiwara

BMC Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer.
Noboru Yamamoto, Miyako Satouchi, Toshihiko Doi, Yutaka Fujiwara, Noriko Yanagitani

Invest New Drugs· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review.
Yutaka Fujiwara, Kazuhiro Shimomura, Teppei Yamaguchi, Junichi Shimizu, Naohiro Watanabe

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease.
Teppei Yamaguchi, Junichi Shimizu, Fumie Shigematsu, Naohiro Watanabe, Takaaki Hasegawa, Yutaka Fujiwara

J Thorac Dis· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current diagnosis and treatment of salivary gland-type tumors of the lung.
Yoshitsugu Horio, Hiroaki Kuroda, Katsuhiro Masago, Hirokazu Matsushita, Eiichi Sasaki, Yutaka Fujiwara

Jpn J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review.
Taigo Kato, Shimon Kurasawa, Kentaro Takezawa, Yutaka Fujiwara, Yoshinari Yasuda

Anticancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, Yuichi Ando, Sumio Hirata, Yutaka Fujiwara

Clin Exp Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022.
Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, Yuichi Ando, Sumio Hirata, Yutaka Fujiwara

Clin Exp Nephrol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Tomohisa Baba, Masahiko Kusumoto, Terufumi Kato, Yasuyuki Kurihara, Shinichi Sasaki, Yutaka Fujiwara

Int J Clin Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Tomohisa Baba, Masahiko Kusumoto, Terufumi Kato, Yasuyuki Kurihara, Shinichi Sasaki, Yutaka Fujiwara

Int J Clin Oncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022.
Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, Nao Takano, Emiko Sakaida, Yutaka Fujiwara

Int J Clin Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito

Cancer Sci· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies.
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara

Cancer Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.
Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, Satoru Iwasa, Kan Yonemori

Cancer Chemother Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
Naohiro Watanabe, Yoshitsugu Horio, Yutaka Fujiwara

Ann Transl Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis